| 000 | 01498 a2200409 4500 | ||
|---|---|---|---|
| 005 | 20250518021033.0 | ||
| 264 | 0 | _c20200611 | |
| 008 | 202006s 0 0 eng d | ||
| 022 | _a1744-8409 | ||
| 024 | 7 |
_a10.1080/1744666X.2019.1573674 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aFrança, Tabata T | |
| 245 | 0 | 0 |
_aCD40 ligand deficiency: treatment strategies and novel therapeutic perspectives. _h[electronic resource] |
| 260 |
_bExpert review of clinical immunology _c05 2019 |
||
| 300 |
_a529-540 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't; Review | ||
| 650 | 0 | 4 | _aAllografts |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aCD40 Antigens _xgenetics |
| 650 | 0 | 4 |
_aCD40 Ligand _xdeficiency |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 | _aGenetic Therapy |
| 650 | 0 | 4 |
_aGranulocyte Colony-Stimulating Factor _xtherapeutic use |
| 650 | 0 | 4 | _aHematopoietic Stem Cell Transplantation |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHyper-IgM Immunodeficiency Syndrome, Type 1 _xgenetics |
| 650 | 0 | 4 |
_aImmunity, Innate _xdrug effects |
| 650 | 0 | 4 | _aMutation |
| 650 | 0 | 4 | _aSurvival Rate |
| 700 | 1 | _aBarreiros, Lucila A | |
| 700 | 1 | _aAl-Ramadi, Basel K | |
| 700 | 1 | _aOchs, Hans D | |
| 700 | 1 | _aCabral-Marques, Otavio | |
| 700 | 1 | _aCondino-Neto, Antonio | |
| 773 | 0 |
_tExpert review of clinical immunology _gvol. 15 _gno. 5 _gp. 529-540 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1080/1744666X.2019.1573674 _zAvailable from publisher's website |
| 999 |
_c29291713 _d29291713 |
||